The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Developing biomarkers to predict immune toxicity risk in NSCLC
Diane Tseng, MD, PhD, Fred Hutch Cancer Center, Seattle, WA, highlights the need for better biomarkers to risk stratify patients with non-small cell lung cancer (NSCLC) prior to immune checkpoint inhibitor therapy, particularly those at risk of severe immune adverse events. Patients with mild immune adverse events tend to have better outcomes than those without toxicities or with severe toxicities, providing a window into the biological determinants of a good immune checkpoint inhibitor response. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There currently do not exist any clinical genomic or immune biomarkers to risk stratify these patients. But I think importantly, there are two clinical implications of our work. I think first is the importance of developing better biomarkers for risk stratifying patients, particularly those who are at risk of developing severe immune adverse events and prior to them receiving immune checkpoint inhibitor therapy...
There currently do not exist any clinical genomic or immune biomarkers to risk stratify these patients. But I think importantly, there are two clinical implications of our work. I think first is the importance of developing better biomarkers for risk stratifying patients, particularly those who are at risk of developing severe immune adverse events and prior to them receiving immune checkpoint inhibitor therapy. And I think that’s where we’re going to make the greatest clinical impact in terms of improving our patient outcomes. I think the second clinical implication of this is the observation that the patients with the mild immune adverse events are actually doing better than the patients who do not experience those toxicities and the patients who develop severe toxicities. And that provides us a window for understanding the underlying biological determinants of a really good immune checkpoint inhibitor response. And I think what we need to do is to better understand the biology so that we can sort of uncouple those really excellent responses from the toxicities that patients are experiencing.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
